The primary purpose of the trial is to assess how effective pregabalin, alprazolam, and placebo are at reducing anxiety levels of subjects who take a dose of these treatments 4 hours before a scheduled dental procedure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
90
Pfizer Investigational Site
Berlin, Germany
Pfizer Investigational Site
Cologne, Germany
Pfizer Investigational Site
Göttingen, Germany
Pfizer Investigational Site
Heidelberg, Germany
Change from baseline to endpoint on the Visual Analogue Scale for Anxiety.
The changes from baseline to endpoint, and changes from baseline to each rating timepoint differ among the three treatment groups for the VAS-Anxiety, VAS-Sedation, Time to Onset of Activity Scales scores, and, Dental Anxiety scales.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
München, Germany
Pfizer Investigational Site
Tübingen, Germany
Pfizer Investigational Site
Manchester, Greater Manchester, United Kingdom
Pfizer Investigational Site
Leeds, West Yorkshire, United Kingdom
Pfizer Investigational Site
Sheffield, United Kingdom